이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy (RESTORE2)

2017년 3월 23일 업데이트: GlaxoSmithKline

Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures

This Phase 3 study is being conducted to evaluate the efficacy and safety of retigabine dosed at 900 mg/day and 600 mg/day, in three equally divided doses, compared with placebo in patients with epilepsy who are receiving up to three established antiepileptic drugs (AEDs).

연구 개요

상세 설명

This Phase 3 study is being conducted in Europe, Israel, Australia, and South Africa to evaluate the efficacy and safety of retigabine dosed at 900 mg/day and 600 mg/day, in three equally divided doses, compared with placebo in patients with epilepsy who are receiving up to three established antiepileptic drugs (AEDs). The primary objective is to demonstrate a superior change in total partial seizure frequency for four weeks from baseline to the double-blind period. The proportion of responders (greater than or equal to 50% reduction in seizure frequency for four weeks from baseline to the double-blind period) will also be evaluated.

연구 유형

중재적

등록 (실제)

539

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Cape Town, 남아프리카, 7550
        • Panorama Medi-Clinic
    • East Cape
      • Port Elizabeth, East Cape, 남아프리카, 6001
        • Triple M Research
    • Gauten
      • Johannesburg, Gauten, 남아프리카, 2193
        • Johannesburg Hospital
    • Gauteng
      • Bloemfontein, Gauteng, 남아프리카, 9300
        • University of the Free State
      • Pretoria, Gauteng, 남아프리카, 0041
        • Wilgers MR & Medical Centre
      • Sunninghill, Gauteng, 남아프리카, 2157
        • Sunninghill & Kopano Clinical Trials
    • KwaZulu-Natal
      • Durban, KwaZulu-Natal, 남아프리카, 4091
        • Inkosi Albert Luthuli Central Hospital
    • West Cape
      • Belville, West Cape, 남아프리카, 7531
        • Carl Bremer Hospital
    • Western Cape
      • Cape Town, Western Cape, 남아프리카, 7925
        • Groote Schuur Hospital
      • Bonn, 독일, D-53105
        • University of Bonn -- Department for Epileptplogy
      • Erlangen, 독일, BY 91054
        • Zentrum Epilepsie Erlangen (ZEE) der Universitaet Erlangen
      • Goettingen, 독일, NI 37075
        • Georg-August-Universitaet Goettingen
      • Mainz, 독일, RP 55101
        • Universitaetsklinik Mainz Neurologische Klinik
      • Marburg, 독일, HE 35033
        • Universitaet Giessen / Marburg Neurologie
      • Munich, 독일, BY 80333
        • Theatinerstrasse 44
      • Ulm, 독일, BW 89081
        • Universitaetsklinikum Ulm
      • Kazan, 러시아 연방, 420048
        • Interregional Clinical Diagnostic Centre
      • Moscow, 러시아 연방, 117049
        • City hospital # 1
      • Moscow, 러시아 연방, 119021
        • Clinic of Nervous Diseases of Sechenov's Moscow Med. Academy
      • Moscow, 러시아 연방, 121374
        • District Antiepileptic Centre City Clinical Hospital # 71
      • St. Petersburg, 러시아 연방, 194044
        • Military Medical Academy n.a. S.M.Kirov
      • St. Petersburg, 러시아 연방, 197022
        • St.Petersburg State Medical University n.a. I.P.Pavlov
    • Maryland
      • Bethesda, Maryland, 미국, 20817
        • Mid-Atlantic Epilepsy and Sleep Center
    • Texas
      • Dallas, Texas, 미국, 75230
        • Neurological Clinic-Texas
      • Antwerp, 벨기에, 2020
        • A. Z. Middelheim -- Department of Neurology
      • Brugge, 벨기에, 8000
        • AZ Sint-Jan
      • Leuven, 벨기에, 3000
        • Universitaire Ziekenhuizen Gasthuisberg -- Department Neurology
      • Ottignies, 벨기에, 1340
        • Centre Neurologique William Lennox
      • Barcelona, 스페인, 08025
        • Hospital de La Santa Creu i Sant Pau
      • Bilbao, 스페인, 48903
        • Hospital De Cruces
      • Granada, 스페인, 18013
        • Hosp. Virgen de las Nieves
      • Madrid, 스페인, 28034
        • Hospital Ruber Internacional de Madrid
      • San Sebastian, 스페인, 20014
        • Hosp de Donostia
      • Zaragoza, 스페인, 50009
        • Hosp. Clinico Univ. Lozano Blesa
      • Blackpool, 영국, LANARK FY3 8BP
        • Fylde Coast Hospital
      • Glasgow, 영국, G11 6NT
        • Western Infirmary (Epilepsy)
      • Liverpool, 영국, L9 7LJ
        • Walton Centre for Neurology & Neurosurgery
      • London, 영국, GT LON E1 1BB
        • Royal London Hospital
    • Mersyd
      • Middlesbrough, Mersyd, 영국, T&W TS4 3BW
        • The James Cook University Hospital
      • Dnepropetrovsk, 우크라이나, 49616
        • Psychosomatic Center of Dnepropetr. Regional Clinic
      • Kharkiv, 우크라이나, 61022
        • Kharkiv State Medical University
      • Kharkov, 우크라이나, 61068
        • Institute of Neurology, Psychiatry and Narcology of AMS, Ukr
      • Kiev, 우크라이나, 04080
        • Epilepsy Center of Municipal Clinical Psychoneurological Hospital
      • Odessa, 우크라이나, 65025
        • Odessa regional clinical Hospital
      • Ashkelon, 이스라엘, 78306
        • Barzilai Medical Center
      • Beer Yaakov, 이스라엘, 70300
        • Assaf Harofeh Medical Center
      • Haifa, 이스라엘, 31096
        • Rambam Medical Center
      • Holon, 이스라엘, 58100
        • Wolfson Medical Center
      • Nahariya, 이스라엘, 22100
        • Western Galilee Hospital
      • Ramat Gan, 이스라엘, 52621
        • Chaim Sheba Medical Center
      • Rechovot, 이스라엘, 76100
        • Kaplan Medical Center
      • Tel Aviv, 이스라엘, 64239
        • Tel-Aviv Sourasky Medical Center
      • Bialystok, 폴란드, 15-420
        • NZOZ Przychodnia Internistyczno - Stomatologiczna "Kendron"
      • Gdansk, 폴란드, 80-803
        • Wojewodzki Szpital Specjalistyczny im.Mikolaja Kopernika
      • Katowice, 폴란드, 40-752
        • Katedra i Klinika Neurologii Slaskiej Akademii Medycznej
      • Lublin, 폴란드, 20-718
        • WSS im.Kardynala S. Wyszynskiego
      • Warsaw, 폴란드, 02-957
        • Instytut Psychiatrii i Neurologii II Oddzial Neurologii
      • Warsaw, 폴란드, 03-464
        • Prywatna Wielospecjalistyczna Lecznica Medyczna "Zycie"
    • Plock
      • Padlewskiego 4, Plock, 폴란드, 09-402
        • Specjalistyczna Przychodnia Lekarska Medikard
      • Rennes Cedex, 프랑스, 35033
        • CHU Pontchaillou
      • Strasbourg, 프랑스, 67 67091
        • Hôpital Civil de Strasbourg
      • Tain L'Hermitage, 프랑스, 26 26600
        • Centre Medical de La Teppe
    • Lyonnais
      • Lyon, Lyonnais, 프랑스, 69003
        • Hopital Neurologique Pierre Wertheimer
      • Budapest, 헝가리, 1145
        • Országos Idegsebészeti Tudományos Intézet
      • Budapest, 헝가리, 1021
        • Natl. Inst. of Psychiatry and Neurology
    • New South Wales
      • Camperdown, New South Wales, 호주, 2050
        • Royal Prince Alfred Hospital
    • Queensland
      • Maroochydore, Queensland, 호주, 4558
        • North Coast Neurology Centre
    • Victoria
      • Clayton, Victoria, 호주, 3168
        • Monash Medical Centre
      • Parkville, Victoria, 호주, 3050
        • Royal Melbourne Hospital
      • West Heidelberg, Victoria, 호주, 3084
        • Austin & Repatriation Medical Centre

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Diagnosis of refractory epilepsy with simple or complex partial onset seizures with or without secondary generalization
  • 28-day partial seizure frequency rate of four or more partial seizures over the 8-week baseline phase
  • Currently treated with up to three established AEDs
  • Vagal Nerve Stimulator may be included

Exclusion Criteria:

  • Existing medical or psychiatric condition which could affect patient's health or compromise ability to participate in the study
  • Clinically significant abnormalities on physical exam, vital signs, ECG, or liver function tests
  • Impaired renal function (creatinine clearance less than 50 mL/minute)
  • Evidence of progressive central nervous disease, lesion, or encephalopathy
  • History of primary generalized seizures
  • History of clustering or flurries or status epilepticus within 12 months of study entry

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
위약 비교기: 위약
구강 정제.
실험적: Retigabine 600 mg
Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 3, patients will enter a 12 week maintenance phase.
다른 이름들:
  • GKE-841
  • D-23129
Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 5, patients will enter a 12 week maintenance phase.
다른 이름들:
  • GKE-841
  • D-23129
실험적: Retigabine 900 mg
Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 3, patients will enter a 12 week maintenance phase.
다른 이름들:
  • GKE-841
  • D-23129
Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 5, patients will enter a 12 week maintenance phase.
다른 이름들:
  • GKE-841
  • D-23129

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Percent Change in the 28-day Total Partial Seizure (PS) Frequency From Baseline (BL) to the End of the Double-blind (DB) Phase (Titration and Maintenance Phases)
기간: Baseline (Week -7 through Week 0), DB Phase (Week 1 through Week 16)
28-day total PS (PSs [also called focal seizures] are seizures limited to a specific area of the brain) frequency in the BL period = (Number [No.] of total PSs reported in the BL period divided by the No. of days of available total PS data in the BL period) x 28 days. 28-day total PS frequency in the DB period = (No. of total PSs reported in the DB period divided by the No. of days of available total PS data in the DB period) x 28 days. Percent change = ([value in the DB period minus value at BL] divided by the BL value) x 100%. Negative valu es indicate a reduction in seizure frequency.
Baseline (Week -7 through Week 0), DB Phase (Week 1 through Week 16)
Number of Participants Classified as Responders and Non-responders During the Maintenance Phase
기간: Week 5 through Week 16
Responders were participants with at least a 50% reduction in the 28-day total partial seizure frequency in the Maintenance Phase as compared to the Baseline period.
Week 5 through Week 16

2차 결과 측정

결과 측정
측정값 설명
기간
Number of Participants Who Were Responders and Non-responders During the DB Phase
기간: Week 1 through Week 16
Responders were participants with at least a 50% reduction in the 28-day total partial seizure frequency in the DB Phase as compared to the Baseline period. Participants without any post-baseline data were considered non-responders.
Week 1 through Week 16
Percent Change From Baseline (BL) in the 28-day Total Partial Seizure Frequency During the Maintenance Phase
기간: Baseline (Week -7 through Week 0), Week 5 through Week 16
28-day total partial seizure frequency in the BL period = (No. of total partial seizures reported in the BL period divided by the No. of days of available total partial seizure data in the BL period) x 28 days. 28-day total partial seizure frequency in the Maintenance Phase = (No. of total partial seizures reported in the Maintenance Phase divided by the No. of days of available total partial seizure data in the same phase) x 28 days. Percent change = (value in the Maintenance Phase minus value at BL divided by the BL value) x 100%. Negative values indicate a reduction in seizure frequency.
Baseline (Week -7 through Week 0), Week 5 through Week 16
Number of Participants With a Reduction in the 28-day Total Partial Seizure Frequency From Baseline to the End of DB Phase (Titration and Maintenance Phases) by Indicated Quartile Reduction Categories
기간: Baseline (Week -7 through Week 0), Week 1 through Week 16
Participants who experienced a reduction from Baseline in the 28-day total partial seizure frequency were categorized as having a reduction of 75-100%, 50-<75%, 25-<50%, or <25%, in addition to having no reduction. This quartile cutting was specified in the study protocol. Participants without any post-baseline data are included in the "No reduction" category.
Baseline (Week -7 through Week 0), Week 1 through Week 16
Number of Participants With a Reduction in the 28-day Total Partial Seizure Frequency From Baseline to the DB Phase (Titration and Maintenance Phases) by Indicated Decile Reduction and Increase Categories
기간: Baseline (Week -7 through Week 0), Week 1 through Week 16
Participants who experienced a reduction from Baseline in the 28-day total partial seizure frequency were categorized in decile cutting, i.e., reduction categories of 90-100%, 80-<90%, 70-<80%, 60-<70%, 50-<60%, 40-<50%, 30-<40%, 20-<30%, 10-<20%, >0-<10%, and increase categories of 0-10%, >10-20%, >20-30%, >30% (FDA endpoint). Participants without any post-baseline data were included in the category 0-10% increase category.
Baseline (Week -7 through Week 0), Week 1 through Week 16
Number of Participants With the Indicated Reduction From Baseline in the 28-day Total Partial Seizure Frequency During the Maintenance Phase
기간: Baseline (Week -7 through Week 0), Week 5 through Week 16
Participants who experienced a reduction from Baseline in the 28-day total partial seizure frequency were categorized as having a >75%, a 50-75%, or a <50% reduction, in addition to having no reduction (EMEA endpoint).
Baseline (Week -7 through Week 0), Week 5 through Week 16
Number of Participants Who Experienced the Indicated Level of Exacerbation and Reduction in the 28-day Total Partial Seizure Frequency From Baseline During the Maintenance Phase
기간: Baseline (Week -7 through Week 0), Week 5 through Week 16
Participants who experienced an exacerbation from Baseline in the 28-day total partial seizure frequency were categorized as having a 0-25% or a >25% increase (EMEA endpoint). The number of participants experiencing a >0% reduction from Baseline in the 28-day total partial seizure frequency are also presented.
Baseline (Week -7 through Week 0), Week 5 through Week 16
Number of Participants Reporting New Seizure Types in the Indicated Categories During the DB Phase (Titration and Maintenance Phases) That Were Not Reported at Baseline
기간: Baseline (Week -7 through Week 0), Week 1 through Week 16
New seizure types included those seizures which were not reported by any participant at Baseline.
Baseline (Week -7 through Week 0), Week 1 through Week 16
Number of Participants Who Were Seizure-free During the DB Phase (Titration and Maintenance Phases)
기간: Week 1 through Week 16
Participants were considered to be seizure-free if they had not reported any seizures during the DB treatment period (Weeks 1-18). For a participant to be seizure free during the DB Phase, the participant had to be seizure free both Week 7 to Week 18 and Week 1 to Week 6. A participant could be seizure free Week 7 to Week 18 (during the Maintenance Phase), but not seizure free Week 1 to Week 6. Hence, there are fewer participants being reported as seizure free from Week 1 to Week 18 than from Week 7 to Week 18.
Week 1 through Week 16
Number of Participants Who Were Seizure-free During the Maintenance Phase
기간: Week 5 through Week 16
Participants were considered to be seizure-free if they had not reported any seizures during the Maintenance Phase.
Week 5 through Week 16
Percentage of Seizure-free Days During the DB Phase (Titration and Maintenance Phases)
기간: Week 1 through Week 16
A seizure-free day was a day without any seizures. For a participant to be seizure free during the DB Phase, the participant had to be seizure free both Week 7 to Week 18 and Week 1 to Week 6. A participant could be seizure free Week 7 to Week 18 (during the Maintenance Phase), but not seizure free Week 1 to Week 6. Hence, there are fewer participants being reported as seizure free from Week 1 to Week 18 than from Week 7 to Week 18. The percentage of seizure-free days was calculated as the total number of days without seizures in the DB period divided by the number of days in DB period x 100%.
Week 1 through Week 16
Percentage of Seizure-free Days During the Maintenance Phase
기간: Week 5 through Week 16
A seizure-free day was a day without any seizures. The percentage of seizure-free days was calculated as the total number of days without seizures in the Maintenance Phase divided by the number of days in the Maintenance Phase x 100%.
Week 5 through Week 16
Clinical Global Impression-Improvement (CGI-I) Score at the End of the Maintenance Phase
기간: Week 16/end of treatment phase
Clinical Global Impression of Improvement (CGI-I) is a 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the treatment. Scores on the scale are rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.
Week 16/end of treatment phase
Patient Global Impression (PGI) Score at the End of the Maintenance Phase
기간: Week 16/end of treatment phase
PGI is a participant-rated scale of improvement that was administered at the end of the Maintenance Phase in order to assess the participant's impression of his or her own improvement. PGI assessments were scored using a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.
Week 16/end of treatment phase
Quality of Life Assessed by Quality of Life in Epilepsy-Problems Questionnaire (QOLIE-31-P) at BL (Week 0) and Weeks 4, 8, and 16
기간: End of Baseline (Week 0), Weeks 4, 8, and 16
The QOLIE-31-P is a 31-item questionnaire evaluating a participant's QOL perception in 7 domains: seizure worry, emotional well being, energy/fatigue, cognitive functioning, medication effects, social functioning, overall QOL. Precoded numeric values for some domains are such that a higher number reflects a more favorable health state; others are such that a higher number reflects a less favorable state. Precoded values are first converted to 0-100 point scores; higher converted scores always reflect better QOL. The overall score is derived by weighting and then summing the 7 domain scores.
End of Baseline (Week 0), Weeks 4, 8, and 16
Number of Participants Whose Clinical Laboratory Values Were Deemed an Adverse Event by the Investigator (>=2% in Any Treatment Arm)
기간: Week 1 through Week 16
Clinically important changes in laboratory values were to be reported as an adverse event if they met one of the following criteria: (1) intervention required; (2) change in dose of study drug required; (3) other treatment/therapy required; (4) association with other diagnoses.
Week 1 through Week 16
Number of Participants Who Reported the Indicated Renal and Urinary Disorder Adverse Events at a Frequency Threshold of 2% (in Any Treatment Arm)
기간: Week 1 through Week 16
A summary of the adverse events classified as renal or urinary disorders and in which at least 2% (rounded to an integer) of participants in any treatment arm reported during the study is presented.
Week 1 through Week 16
Change From Baseline in Post-void Residual Urine Volume at Weeks 8 and 16 of the Maintenance Phase
기간: Baseline (Week -7 through 0), Weeks 8 and 16
Post-void residual (PVR) urine refers to the amount of urine remaining in the bladder after normal urination. To investigate the possible effects of retigabine on bladder function, all participants underwent post-void residual bladder ultrasound at Baseline and during the Maintenance Phase. The PVR bladder ultrasound was performed by a urologist, a qualified ultrasound technician, or a qualified study nurse who was certified to do PVR bladder ultrasound. Change from Baseline in PVR residual volume was calculated as the values at Week 10 and Week 16 minus the value at Baseline.
Baseline (Week -7 through 0), Weeks 8 and 16
Number of Participants With a >=7% Increase in Body Weight During Weeks 2 and 4 of theTitration Phase and Weeks 6, 8, 12, and 16 of the Maintenance Phase
기간: Weeks 2 and 4 of Titration Phase and Weeks 6, 8, 12, and 16 of Maintenance Phase
The number of participants with recorded weight gain of >=7% over their baseline weight was measured.
Weeks 2 and 4 of Titration Phase and Weeks 6, 8, 12, and 16 of Maintenance Phase

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2005년 12월 1일

기본 완료 (실제)

2008년 4월 1일

연구 완료 (실제)

2008년 4월 1일

연구 등록 날짜

최초 제출

2005년 10월 6일

QC 기준을 충족하는 최초 제출

2005년 10월 6일

처음 게시됨 (추정)

2005년 10월 10일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2017년 4월 21일

QC 기준을 충족하는 마지막 업데이트 제출

2017년 3월 23일

마지막으로 확인됨

2017년 3월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

연구 데이터/문서

  1. 연구 프로토콜
    정보 식별자: VRX-RET-E22-302
    정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
  2. 개별 참가자 데이터 세트
    정보 식별자: VRX-RET-E22-302
    정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
  3. 주석이 달린 사례 보고서 양식
    정보 식별자: VRX-RET-E22-302
    정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
  4. 임상 연구 보고서
    정보 식별자: VRX-RET-E22-302
    정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
  5. 통계 분석 계획
    정보 식별자: VRX-RET-E22-302
    정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
  6. 데이터 세트 사양
    정보 식별자: VRX-RET-E22-302
    정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
  7. 정보에 입각한 동의서
    정보 식별자: VRX-RET-E22-302
    정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다